Abcellera Biologics Inc (ABCL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2025 | 12-2024 | 09-2024 | 06-2024 | 03-2024 | |
| Sales | 4,235 | 5,049 | 6,507 | 7,323 | 9,954 |
| Gross Profit | 4,235 | 5,049 | 6,507 | 7,323 | 9,954 |
| Operating Expenses | 66,895 | 77,804 | 100,170 | 100,777 | 64,848 |
| Operating Income | -62,660 | -72,755 | -93,663 | -93,454 | -54,894 |
| Other Income | 9,676 | 25,926 | 31,031 | 45,267 | 12,147 |
| Pre-tax Income | -52,984 | -46,829 | -62,632 | -48,187 | -42,747 |
| Income Tax | -7,363 | -12,619 | -11,525 | -11,257 | -2,137 |
| Net Income Continuous | -45,621 | -34,210 | -51,107 | -36,930 | -40,610 |
| Net Income | $-45,621 | $-34,210 | $-51,107 | $-36,930 | $-40,610 |
| EPS Basic Total Ops | -0.15 | -0.11 | -0.17 | -0.13 | -0.14 |
| EPS Basic Continuous Ops | -0.15 | -0.12 | -0.17 | -0.13 | -0.14 |
| EPS Diluted Total Ops | -0.15 | -0.11 | -0.17 | -0.13 | -0.14 |
| EPS Diluted Continuous Ops | -0.15 | -0.12 | -0.17 | -0.13 | -0.14 |
| EPS Diluted Before Non-Recurring Items | -0.15 | -0.11 | -0.17 | -0.13 | N/A |
| EBITDA(a) | $-56,055 | $-58,855 | $-55,368 | $-55,417 | $-48,128 |